Final Logo-01.png
Achondroplasia Treatment Market Projected to Reach USD 3.2 Billion by 2034, Unveils Dynamics, Segmentation, and Growth Opportunities – By PMI
01. Februar 2024 07:01 ET | PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Achondroplasia Treatment Market size was valued at about USD 120.4 million in 2024 and expected to grow at CAGR...
logo.jpg
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
03. März 2022 07:30 ET | Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BridgeBio Pharma, Inc. Merger
02. Dezember 2020 14:39 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO) regarding possible breaches...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Eidos Therapeutics, Inc. Buyout
05. Oktober 2020 21:00 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ GS: EIDX) regarding possible breaches of...